BioCentury
ARTICLE | Clinical News

Inspiolto Respimat: Additional Phase III data

February 15, 2016 8:00 AM UTC

Additional data from the double-blind, crossover, international Phase III ENERGITO trial in about 229 patients with moderate to severe COPD showed that once-daily oral Stiolto Respimat improved FEV1 A...